677 related articles for article (PubMed ID: 14607902)
1. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
[TBL] [Abstract][Full Text] [Related]
2. In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen).
Goldberg J; Shrikant P; Mescher MF
J Immunol; 2003 Jan; 170(1):228-35. PubMed ID: 12496404
[TBL] [Abstract][Full Text] [Related]
3. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.
Krishnan L; Sad S; Patel GB; Sprott GD
J Immunol; 2000 Nov; 165(9):5177-85. PubMed ID: 11046050
[TBL] [Abstract][Full Text] [Related]
4. Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor.
Guiducci C; Di Carlo E; Parenza M; Hitt M; Giovarelli M; Musiani P; Colombo MP
J Immunol; 2004 Apr; 172(7):4026-36. PubMed ID: 15034014
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.
Jackaman C; Nelson DJ
Cancer Immunol Immunother; 2012 Apr; 61(4):549-60. PubMed ID: 22002241
[TBL] [Abstract][Full Text] [Related]
6. Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells.
Rubinstein MP; Kadima AN; Salem ML; Nguyen CL; Gillanders WE; Cole DJ
J Immunol; 2002 Nov; 169(9):4928-35. PubMed ID: 12391205
[TBL] [Abstract][Full Text] [Related]
7. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL.
Nelson DJ; Mukherjee S; Bundell C; Fisher S; van Hagen D; Robinson B
J Immunol; 2001 May; 166(9):5557-66. PubMed ID: 11313395
[TBL] [Abstract][Full Text] [Related]
8. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
9. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors.
Nair RE; Kilinc MO; Jones SA; Egilmez NK
J Immunol; 2006 Jun; 176(12):7325-34. PubMed ID: 16751376
[TBL] [Abstract][Full Text] [Related]
10. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
11. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes.
Blohm U; Roth E; Brommer K; Dumrese T; Rosenthal FM; Pircher H
J Immunol; 2002 Nov; 169(10):5522-30. PubMed ID: 12421928
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy.
Narvaiza I; Mazzolini G; Barajas M; Duarte M; Zaratiegui M; Qian C; Melero I; Prieto J
J Immunol; 2000 Mar; 164(6):3112-22. PubMed ID: 10706701
[TBL] [Abstract][Full Text] [Related]
13. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
[TBL] [Abstract][Full Text] [Related]
14. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response.
Gri G; Gallo E; Di Carlo E; Musiani P; Colombo MP
J Immunol; 2003 Jan; 170(1):99-106. PubMed ID: 12496388
[TBL] [Abstract][Full Text] [Related]
15. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells.
Salcedo R; Stauffer JK; Lincoln E; Back TC; Hixon JA; Hahn C; Shafer-Weaver K; Malyguine A; Kastelein R; Wigginton JM
J Immunol; 2004 Dec; 173(12):7170-82. PubMed ID: 15585838
[TBL] [Abstract][Full Text] [Related]
16. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
17. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity.
Marzo AL; Kinnear BF; Lake RA; Frelinger JJ; Collins EJ; Robinson BW; Scott B
J Immunol; 2000 Dec; 165(11):6047-55. PubMed ID: 11086036
[TBL] [Abstract][Full Text] [Related]
18. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
19. The adjuvant effects of Mycobacterium tuberculosis heat shock protein 70 result from the rapid and prolonged activation of antigen-specific CD8+ T cells in vivo.
Harmala LA; Ingulli EG; Curtsinger JM; Lucido MM; Schmidt CS; Weigel BJ; Blazar BR; Mescher MF; Pennell CA
J Immunol; 2002 Nov; 169(10):5622-9. PubMed ID: 12421941
[TBL] [Abstract][Full Text] [Related]
20. Molecular and cellular requirements for enhanced antigen cross-presentation to CD8 cytotoxic T lymphocytes.
Oizumi S; Strbo N; Pahwa S; Deyev V; Podack ER
J Immunol; 2007 Aug; 179(4):2310-7. PubMed ID: 17675492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
